HOLX Hologic, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
31.20
PEG
—
P/B
3.25
P/S
4.11
EV/EBITDA
17.08
DCF Value
$108.60
FCF Yield
5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.8%
Operating Margin
17.5%
Net Margin
13.2%
ROE
11.0%
ROA
5.9%
ROIC
7.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $1.05B | $179.1M | $— |
| Q4 null | $1.05B | $187.3M | $— |
| FY null | $4.10B | $565.7M | $— |
| Q3 null | $1.02B | $194.9M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$78.69
Target (Median)
$78.50
Target Range
$33.00 - $95.00
Trading Activity
Insider Trades
View AllCongress Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.70
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.